Vertex Pharmaceuticals Lands on Goldman Sachs Highest-Conviction List

Goldman Sachs recently added Vertex Pharmaceuticals to its highest-conviction list with a 'buy' rating and a $653 price target. The biotech company's shares are currently trading at $546, but analysts have vastly different predictions for the stock's future.

Vertex's core business is generating consistent revenue and earnings from its cystic fibrosis (CF) treatments, which have virtually no competition in the market. However, the company has been expanding into new areas with newer launches such as Casgevy, a gene-editing medicine for rare blood diseases, and Journavx, a therapy for acute pain.

Vertex's portfolio now features Palsonify, a medicine approved last year for acromegaly, a rare disorder that causes patients' bones and organs to grow larger than normal. The company also acquired Crinetics Pharmaceuticals for $10 billion in cash, gaining atumelnant, an investigational medicine in phase 3 clinical trials for congenital adrenal hyperplasia.

Vertex estimates that Palsonify and atumelnant could generate more than $5 billion in combined peak sales. The company's pipeline also includes inaxaplin, a potential medicine for APOL-1-mediated kidney disease, as well as other assets in phase 2 and phase 3 clinical trials.